{"protocolSection":{"identificationModule":{"nctId":"NCT06014723","orgStudyIdInfo":{"id":"BLAST"},"organization":{"fullName":"The First Hospital of Jilin University","class":"OTHER"},"briefTitle":"Balloon angiopLasty for Intracranial Atherosclerotic Minor Stroke/TIA","officialTitle":"Balloon angiopLasty for Intracranial Atherosclerotic Minor Stroke/TIA: a Prospective, Multi-center, Register Study"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-08-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-08-21","studyFirstSubmitQcDate":"2023-08-25","studyFirstPostDateStruct":{"date":"2023-08-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-02","lastUpdatePostDateStruct":{"date":"2024-01-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Shouchun Wang, MD, PhD","investigatorTitle":"Chief physician of the Department of Neurology","investigatorAffiliation":"The First Hospital of Jilin University"},"leadSponsor":{"name":"Shouchun Wang, MD, PhD","class":"OTHER"},"collaborators":[{"name":"The General Hospital of Northern Theater Command","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of this study was to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke/transient ischemic attack with intracranial atherosclerosis etiology.","detailedDescription":"In this study, 416 patients with minor strokes or transient ischemic attacks due to symptomatic intracranial atherosclerotic stenosis within one week of the onset of last ischemic symptoms from 20 centers in China were enrolled. The observation group received early submaximal balloon angioplasty, while the control group received only medical therapy. Two groups will be followed up for 1 year to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke / transient ischemic attack with intracranial atherosclerosis etiology."},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":416,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Observation group","description":"The observation group received early submaximal balloon angioplasty and medical therapy.","interventionNames":["Procedure: Submaximal balloon angioplasty"]},{"label":"Control group","description":"The control group received only medical therapy."}],"interventions":[{"type":"PROCEDURE","name":"Submaximal balloon angioplasty","description":"The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.","armGroupLabels":["Observation group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Stroke or death within 30 days or ischemic stroke in the culprit artery territory from 30 days to 1 year","description":"Stroke or death within 30 days or ischemic stroke in the culprit artery territory from 30 days to 1 year","timeFrame":"30 days, 1 year"}],"secondaryOutcomes":[{"measure":"Stroke or death within 30 days after enrollment","description":"Stroke or death within 30 days after enrollment","timeFrame":"30 days"},{"measure":"Ischemic stroke in the territory of criminal artery from 30 days to 1 year after enrollment","description":"Ischemic stroke in the territory of criminal artery from 30 days to 1 year after enrollment","timeFrame":"1 year"},{"measure":"Restenosis rate of criminal artery within 1 year after enrollment","description":"Restenosis rate of criminal artery within 1 year after enrollment","timeFrame":"1 year"},{"measure":"Evaluation of neurological function improvement within 90 days of enrollment","description":"Evaluation of neurological function improvement within 90 days of enrollment","timeFrame":"90 days"}],"otherOutcomes":[{"measure":"Intracranial hemorrhage within 30 days of enrollment","description":"Intracranial hemorrhage within 30 days of enrollment","timeFrame":"30 days"},{"measure":"Complications associated with endovascular therapy","description":"Complications associated with endovascular therapy","timeFrame":"24 hours, discharge, 30 days, 90 days, and 1 year after enrollment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. age range of 30-80 years;\n2. symptomatic ICAS (C4-C7 segments of ICA, M1 segment of the MCA, V4 segment of the VA, and BA) with 70%-99% stenosis confirmed by DSA;\n3. minor stroke (NIHSS score ≤5) within 1 week of onset or from symptom exacerbation (NIHSS score increased by ≥2 points) or intermediate- to high-risk TIA, defined as ABCD2 score ≥4 within 1 week of the last symptom episode;\n4. diameter of the culprit artery ranging from 2.0 to 4.5mm, and the length of the stenosis≤14mm;\n5. mRS ≤ 2 before endovascular treatment；\n6. no large ischemic region found on CT or MRI (ASPECTS≥ 6 or pc-ASPECTS ≥8)；\n7. written informed consent obtained from the patient or legally responsible person.\n\nExclusion Criteria:\n\n1. allergy to contrast media;\n2. non-atherosclerotic disease-related stenosis, such as arterial dissection, Moya-Moya disease, and arteritis;\n3. penetrating branch lesion ipsilateral to the target lesion (infarction caused by penetrating branch occlusion is defined as stenosis of the MCA or BA, but only with simple basal ganglia or brainstem/thalamic infarction);\n4. presence of severe stenosis of the extracranial segment on the side of the target lesion;\n5. previous endovascular treatment of the ipsilateral vessel;\n6. presence of intracranial aneurysms, tumors, and vascular malformations;\n7. any form of ipsilateral intracranial hemorrhage within 3 months and contralateral intracranial hemorrhage within 2 weeks;\n8. presence of atrial fibrillation, severe heart dysfunction, liver or kidney dysfunction; patients with tumors and serious diseases whose expected survival time is ≤ 1 year;\n9. hemoglobin ≤ 100g/L, platelet count ≤ 100×10\\^9/L, INR\\> 1.5 (irreversible), coagulopathy or irremediable bleeding factors;\n10. uncontrollable hypertension: systolic blood pressure \\>185 mmHg and/or diastolic blood pressure \\>110 mmHg;\n11. poor glycemic control (random blood glucose \\> 22.2 mmol/L);\n12. history of major surgery within 30 days prior to enrollment or surgery plan within 90 days after enrollment;\n13. pregnancy or lactation;\n14. other conditions that the researchers think make the patient unsuitable for the study.","sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with minor stroke/transient ischemic attack.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Shouchun Wang, MD, PhD","role":"CONTACT","phone":"0086-13596060906","email":"WSC@jlu.edu.cn"},{"name":"Huisheng Chen, MD, PhD","role":"CONTACT","phone":"0086-13352452086","email":"chszh@aliyun.com"}],"locations":[{"facility":"The First Hospital of Jilin University","status":"RECRUITING","city":"Changchun","state":"Jilin","zip":"130000","country":"China","contacts":[{"name":"Shouchun MD Wang, MD,PhD","role":"CONTACT","phone":"13596060906","phoneExt":"0086","email":"WSC@jlu.edu.cn"}],"geoPoint":{"lat":43.88,"lon":125.32278}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}